Read this company snapshot
Daily valuation snapshot
Denali Therapeutics Inc. Common Stock: source evidence dated 2026-10-09.
- Daily close (USD)
- $19.45
- Market capitalization (USD)
- $3,109,031,988.35
- Price / earnings (TTM)
- Not reported
- Price / book
- 3.72
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research DNLI in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research DNLI in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing DNLI with another company.
| Daily close (USD) | $19.45 |
| Market capitalization (USD) | $3,109,031,988.35 |
| Price / earnings (TTM) | Not reported |
| Price / book | 3.72 |
No matching rows. Clear the filter to see all records.
Read DNLI's valuation metrics
Company size
Denali Therapeutics Inc. Common Stock's recorded market capitalization is $3,109,031,988.35. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
DNLI's recorded price-to-book ratio is 3.72. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Denali Therapeutics Inc. Common Stock with Aurora
Use the snapshot above to ask a specific question about DNLI. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow DNLI's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.